登录 | 注册    关注公众号  
微信公众号
搜索
 >  Protein>Fc gamma RIIB / CD32b >CDB-C82E4

Biotinylated Cynomolgus Fc gamma RIIB / CD32b Protein, His,Avitag™ (SPR & BLI & MALS verified)

热销产品推荐:

利用生物素-链霉亲和素系统的高特异性和高灵敏度的结合特性,可将生物素化蛋白与链霉亲和素相关产品联合应用于各类实验,与非生物素体系相比,检测速度更快、结合能力更强、非特异背景更低。

分子别名(Synonym)

FCGR

表达区间及表达系统(Source)

Biotinylated Cynomolgus CD32b, His,Avitag (CDB-C82E4) is expressed from human 293 cells (HEK293). It contains AA Ala 46 - Pro 224 (Accession # Q8SPW3-1).

Predicted N-terminus: Ala 46

Request for sequence

蛋白结构(Molecular Characterization)

Fc gamma RIIB / CD32b Structure

This protein carries a polyhistidine tag at the C-terminus, followed by an Avi tag (Avitag™).

The protein has a calculated MW of 23.6 kDa. The protein migrates as 30-35 kDa under reducing (R) condition (SDS-PAGE) due to glycosylation.

标记(Labeling)

Biotinylation of this product is performed using Avitag™ technology. Briefly, the single lysine residue in the Avitag is enzymatically labeled with biotin.

蛋白标记度(Protein Ratio)

Passed as determined by the HABA assay / binding ELISA.

内毒素(Endotoxin)

Less than 1.0 EU per μg by the LAL method.

纯度(Purity)

>95% as determined by SDS-PAGE.

>90% as determined by SEC-MALS.

制剂(Formulation)

Lyophilized from 0.22 μm filtered solution in PBS, pH7.4 with trehalose as protectant.

Contact us for customized product form or formulation.

重构方法(Reconstitution)

Please see Certificate of Analysis for specific instructions.

For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.

存储(Storage)

For long term storage, the product should be stored at lyophilized state at -20°C or lower.

Please avoid repeated freeze-thaw cycles.

This product is stable after storage at:

  1. -20°C to -70°C for 12 months in lyophilized state;
  2. -70°C for 12 months under sterile conditions after reconstitution.
 

电泳(SDS-PAGE)

Fc gamma RIIB / CD32b SDS-PAGE

Biotinylated Cynomolgus CD32b, His,Avitag on SDS-PAGE under reducing (R) condition. The gel was stained with Coomassie Blue. The purity of the protein is greater than 95%.

SEC-MALS

Fc gamma RIIB / CD32b SEC-MALS

The purity of Biotinylated Cynomolgus CD32b, His,Avitag (Cat. No. CDB-C82E4) is more than 90% and the molecular weight of this protein is around 35-45 kDa verified by SEC-MALS.

Report

 

活性(Bioactivity)-SPR

Fc gamma RIIB / CD32b SPR

Captured Biotinylated Cynomolgus Fc gamma RIIB / CD32b, His Tag, Avi Tag Protein (Cat. No. CDB-C82E4) on Biotin CAP - Series S sensor Chip can bind Rituximab biosimilar (Cat. No. CD0-M36) with an affinity constant of 4.52 μM as determined in a SPR assay (Biacore T200) (QC tested).

Protocol

 

活性(Bioactivity)-BLI

Fc gamma RIIB / CD32b BLI

Loaded Biotinylated Cynomolgus CD32b, His,Avitag (Cat. No. CDB-C82E4) on SA Biosensor, can bind MabThera® (Rituximab) with an affinity constant of 1.3 μM as determined in BLI assay (ForteBio Octet Red96e) (Routinely tested).

Protocol

 

背景(Background)

Receptors for the Fc region of IgG (Fc γ R) are members of the Ig superfamily that function in the activation or inhibition of immune responses. Three classes of human Fc γ Rs: RI (CD64), RII (CD32), and RIII (CD16), which generate multiple isoforms, are recognized.
There are three genes for human Fcγ RII /CD32 (A, B, and C) and one for mouse Fcγ RII B (CD32B). CD32 is a low affinity receptor for IgG. Low affinity immunoglobulin gamma Fc region receptor II-b (FCGR2B) is also known as CD32b, FCG2, IGFR2. CD32B is expressed on B cells and myeloid dendritic cells. Ligation of CD32B on B cells downregulates antibody production and may, in some circumstances, promote apoptosis. Co-ligation of CD32B on dendritic cells inhibits maturation and blocks cell activation. CD32B may also be a target for monoclonal antibody therapy for malignancies.

 

前沿进展

 
 
货号/价格
产品推荐
文档
联系电话:
+86 400-682-2521(全国)
010-53681107(北京)
021-50850665(上海)
运输方式
订单邮箱:
order.cn@acrobiosystems.com
技术支持邮箱:
tech.cn@acrobiosystems.com
Fc gamma RIIB / CD32b靶点信息
英文全称:Low affinity immunoglobulin gamma Fc region receptor II-b
中文全称:低亲和力免疫球蛋白γFc区受体II-B
种类:Homo sapiens
上市药物数量:0详情
临床药物数量:4详情
最高研发阶段:临床三期
查看更多信息
前沿进展
点击查看详细

消息提示

请输入您的联系方式,再点击提交!

确定